Lv3
268 积分 2024-03-29 加入
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
1个月前
已完结
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases
1个月前
已完结
An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis
2个月前
已完结
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus
2个月前
已完结
Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations
2个月前
已完结
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
3个月前
已完结
Exploring the next generation of antibody–drug conjugates
6个月前
已完结
STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems
6个月前
已完结
The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus
7个月前
已完结
DB-2304, a Duality Immune Modulating Antibody‒Drug Conjugate (DIMAC) targeting BDCA2, displays strong potency in the suppression of pDC functions
7个月前
已完结
皖公网安备34019202002308
